Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Prices Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland, July 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of 22,222,223 American Depositary Shares ("ADSs") at a price to the public of $18.00 per ADS.
View HTML
Toggle Summary Amarin Announces $400,000,000 Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland, July 17, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced an underwritten public offering of $400,000,000 of its American Depositary Shares pursuant to a shelf registration.
View HTML
Toggle Summary Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance
Record Revenue Achieved in 1H19 Primarily Due to Increased Demand for Vascepa Guidance for Total 2019 Revenue Increased to a Range of $380 to $420 Million from $350 Million Following Unaudited Second Quarter Results Estimated Between $97 and $101 Million, or Between $170 and $174 Million for the
View HTML
Toggle Summary Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences
BEDMINSTER, N.J. and DUBLIN, Ireland, June 21, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, June 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting
Approximately 10 Million People with Diabetes Are at Elevated Risk of  Cardiovascular Disease 1,2 In a release issued under the same headline earlier today by  Amarin Corporation plc (NASDAQ: AMRN), please note the copy has been updated to directly focus on Amarin’s presentations for the 2019 ADA
View HTML
Toggle Summary Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications
BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice president of Corporate
View HTML
Toggle Summary Amarin to Present at the Jefferies 2019 Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
 - PDUFA date assigned is September 28, 2019, four months sooner than expected  - Vascepa , assuming approval, will be first drug indicated to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, as studied in the landmark
View HTML

Amarin Corporation